01

Phase 2 Trial Tests High-Induction Risankizumab in Plaque Psoriasis

A randomized phase 2 trial in Nature tests high-induction dosing of risankizumab in moderate-to-severe plaque psoriasis, probing whether front-loaded dosing speeds clearance.